AbCellera Biologics Inc.
Developer of an integrated antibody discovery and development platform that combines microfluidics-based single-cell screening, high-throughput sequencing, automated instrumentation, data science and protein science with CMC and clinical manufacturing capabilities. The platform supports target assessment, discovery, IND-enabling studies and early clinical manufacturing. The company has operated through partnerships on 100+ discovery programs and has shifted toward advancing internal and co-development therapeutic antibody programs.
Industries
Nr. of Employees
large (251-1000)
AbCellera Biologics Inc.
150 W 4th Ave, Vancouver, BC V5Y 1G6, Canada
Patents
Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor
US-9512181-B2
View Details
Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor
US-9512181-B2
View DetailsProducts
Internal therapeutic antibody programs (clinical-stage candidates)
In-house discovery-to-IND therapeutic antibody programs advanced using the integrated platform; programs include candidates targeting GPCRs and immune targets with engineered Fc modifications.
Internal therapeutic antibody programs (clinical-stage candidates)
In-house discovery-to-IND therapeutic antibody programs advanced using the integrated platform; programs include candidates targeting GPCRs and immune targets with engineered Fc modifications.
Services
Integrated workflows from target assessment, single-cell functional screening, sequence analysis, protein engineering and preclinical characterization through IND-enabling studies.
Structuring and managing research collaborations, licensing of assets, and alliance governance to advance antibody programs with partners.
Design, build, qualification and operational support for clinical CMC laboratories and GMP manufacturing facilities to produce drug substance and drug product for clinical trials.
Integrated workflows from target assessment, single-cell functional screening, sequence analysis, protein engineering and preclinical characterization through IND-enabling studies.
Structuring and managing research collaborations, licensing of assets, and alliance governance to advance antibody programs with partners.
Design, build, qualification and operational support for clinical CMC laboratories and GMP manufacturing facilities to produce drug substance and drug product for clinical trials.
Expertise Areas
- Therapeutic antibody discovery and engineering
- Single-cell screening and high-throughput functional assays
- Target assessment and prioritization
- Protein expression for complex membrane proteins
Key Technologies
- Microfluidic single-cell screening
- Immune-repertoire / next-generation sequencing
- Automation and machine-vision imaging for screening
- Cloud-scale data pipelines and ML-driven bioinformatics
News & Updates
Multiple posters and presentations on T-cell engagers and bispecific design at AACR annual meetings.
Hosted an R&D Day focused on antibody development against challenging targets and strategies for translational success.
Poster presenting preclinical efficacy data for PSMA x CD3 T-cell engager constructs for prostate cancer (Abstract #6012).
Rapid identification and advancement of a neutralizing antibody from a recovered patient to first-in-human testing in under three months, enabled by accelerated discovery workflows.
Listings of regulatory authorizations to initiate Phase 1 trials for internal programs and presentation of preclinical data at scientific meetings.
Completed over 100 therapeutic antibody discovery programs through partnerships.
Multiple posters and presentations on T-cell engagers and bispecific design at AACR annual meetings.
Hosted an R&D Day focused on antibody development against challenging targets and strategies for translational success.
Poster presenting preclinical efficacy data for PSMA x CD3 T-cell engager constructs for prostate cancer (Abstract #6012).
Rapid identification and advancement of a neutralizing antibody from a recovered patient to first-in-human testing in under three months, enabled by accelerated discovery workflows.
Listings of regulatory authorizations to initiate Phase 1 trials for internal programs and presentation of preclinical data at scientific meetings.
Completed over 100 therapeutic antibody discovery programs through partnerships.